Investor + Media Resources

GT-30: Clinical Updates
June 3, 2021

Geneos announced positive preliminary results of our ongoing first-in-human trial GT-30. GT-30 is a  phase I/II trial of personalized vaccine, GNOS-PV02, in combination with plasmid pIL-12 and pembrolizumab in patients in second line advanced hepatocellular carcinoma (HCC).

View PDF

GT-30: Clinical Expansion
March 16, 2021

VGXI and Geneos Therapeutics Expand Partnership for Personalized Cancer Immunotherapies

View PDF

Geneos closes Series A1 Financing
March 3, 2021

Geneos Therapeutics Secures $12 Million in Series A1 Financing to Advance Personalized Cancer Immunotherapy Programs

Geneos expands its lead program for treating patients with advanced hepatocellular carcinoma

Geneos adds to its leadership team

View PDF

Upcoming Conferences
February 6, 2021

Geneos will be attending the following upcoming conferences:

  • ASCO, June 2021
  • BIO Digital, June 2021
  • International Cancer Cluster Showcase, June 2021

GT-30: cGMP Manufacturing of First Clinical Lot
May 18, 2020

VGXI Enables Rapid GMP DNA Manufacturing Timeline for Geneos Therapeutics Personalized Cancer Immunotherapy

View PDF

Hepatocellular Carcinoma Trial
February 3, 2020

Geneos Personalized Neoantigen-Targeting Vaccine (GNOS-PV02) to be Utilized in Innovative GT-30 Hepatocellular Carcinoma Trial


View PDF

Lyfebulb-Helsinn Cancer Innovation Summit & Award
January 30, 2020

Geneos Therapeutics Named One of 11 Finalists for the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award. Niranjan Y. Sardesai, CEO of Geneos, presented at the Lyfebulb Helsinn Cancer Innovation Summit on January 30th, 2020 in Monaco.

Establish Supply Agreement
July 19, 2019

Texas Based CMO VGXI and Geneos Therapeutics Establish Supply Agreement for Production of GT- EPIC-Based Personalized Cancer Therapeutics

View PDF